THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) IS AT THE FOREFRONT OF THE FIGHT TO CURE BLOOD CANCER.
We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we’ve invested more than $1.7 billion in groundbreaking research, pioneering many of today’s most innovative approaches.
LLS IS A GLOBAL LEADER IN THE FIGHT AGAINST BLOOD CANCER.
The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
RESEARCH
We are the largest nonprofit funder of blood cancer research, investing more than $1.7 billion in the most pioneering science worldwide since 1949.
EDUCATION & SUPPORT
We are the leading source of free education and support for blood cancer patients and families. We provide personalized, one-on-one support, including assistance with identifying and enrolling in a clinical trial.
POLICY & ADVOCACY
With our nationwide grassroots network of more than 50,000 active online volunteers, we drive policy changes that accelerate the development of new cancer treatments and break down barriers to care.
OUR IMPACT
INVESTED MORE THAN
$1.7B
IN CANCER RESEARCH SINCE 1949
FUNDING NEARLY
200
RESEARCH GRANTS AROUND THE WORLD
MORE THAN
$234M
PROVIDED IN CO-PAY FINANCIAL ASSISTANCE
HELPED ADVANCE
70%
OF THE BLOOD CANCER TREATMENT OPTIONS APPROVED BY THE FDA SINCE 2017
Staff
Blaine Robinson, Ph.D.
Dr. Blaine Robinson joined LLS in 2011 and was recently promoted in April 2019 to Executive Director for the Therapy Acceleration Program (TAP), the venture philanthropy initiative of LLS.
Jun Xu, Ph.D.
Dr. Jun Xu joined LLS in 2011. LLS Therapy Acceleration Program (TAP) seeks to fund clinical development of therapies or diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.
Lore Gruenbaum, Ph.D.
Dr. Lore Gruenbaum joined LLS in 2020 as the Vice President for the Therapy Acceleration Program (TAP), the LLS venture philanthropy program aiming to accelerate high-risk, innovative blood cancer therapeutics.